Abstract
Aims: To evaluate the immunogenicity, safety and tolerability of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis (JIA). Methods: Twenty-one patients with JIA aged 12-25 years and 21 healthy controls were enrolled and received three doses of the bivalent HPV vaccine. Results: All of the subjects were seronegative at baseline and seroconverted after the scheduled doses. The JIA patients showed significantly lower HPV16 neutralising antibody titres than controls 1 month after the administration of the third dose (p <0.05), whereas no significant difference was observed in HPV18 neutralising antibody titres. Local and systemic reactions were similarly frequent in the patients and controls, and there were no significant changes in 27-joint juvenile arthritis disease activity score or laboratory tests. Conclusion: The bivalent HPV vaccine is safe in patients with stable JIA and regardless of the use of medications the vaccine assures an adequate degree of protection for a certain time.
| Original language | English |
|---|---|
| Pages (from-to) | 1387-1393 |
| Number of pages | 7 |
| Journal | Expert Review of Vaccines |
| Volume | 13 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 1 2014 |
Fingerprint
Keywords
- autoimmune disease
- bivalent papillomavirus vaccine
- HPV
- juvenile idiopathic arthritis
- papillomavirus vaccine
- rheumatological disease
ASJC Scopus subject areas
- Immunology
- Drug Discovery
- Pharmacology
- Molecular Medicine
- Medicine(all)
Cite this
Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis. / Esposito, Susanna; Corona, Fabrizia; Barzon, Luisa; Cuoco, Federica; Squarzon, Laura; Marcati, Giorgia; Torcoletti, Marta; Gambino, Monia; Palù, Giorgio; Principi, Nicola.
In: Expert Review of Vaccines, Vol. 13, No. 11, 01.11.2014, p. 1387-1393.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis
AU - Esposito, Susanna
AU - Corona, Fabrizia
AU - Barzon, Luisa
AU - Cuoco, Federica
AU - Squarzon, Laura
AU - Marcati, Giorgia
AU - Torcoletti, Marta
AU - Gambino, Monia
AU - Palù, Giorgio
AU - Principi, Nicola
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Aims: To evaluate the immunogenicity, safety and tolerability of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis (JIA). Methods: Twenty-one patients with JIA aged 12-25 years and 21 healthy controls were enrolled and received three doses of the bivalent HPV vaccine. Results: All of the subjects were seronegative at baseline and seroconverted after the scheduled doses. The JIA patients showed significantly lower HPV16 neutralising antibody titres than controls 1 month after the administration of the third dose (p <0.05), whereas no significant difference was observed in HPV18 neutralising antibody titres. Local and systemic reactions were similarly frequent in the patients and controls, and there were no significant changes in 27-joint juvenile arthritis disease activity score or laboratory tests. Conclusion: The bivalent HPV vaccine is safe in patients with stable JIA and regardless of the use of medications the vaccine assures an adequate degree of protection for a certain time.
AB - Aims: To evaluate the immunogenicity, safety and tolerability of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis (JIA). Methods: Twenty-one patients with JIA aged 12-25 years and 21 healthy controls were enrolled and received three doses of the bivalent HPV vaccine. Results: All of the subjects were seronegative at baseline and seroconverted after the scheduled doses. The JIA patients showed significantly lower HPV16 neutralising antibody titres than controls 1 month after the administration of the third dose (p <0.05), whereas no significant difference was observed in HPV18 neutralising antibody titres. Local and systemic reactions were similarly frequent in the patients and controls, and there were no significant changes in 27-joint juvenile arthritis disease activity score or laboratory tests. Conclusion: The bivalent HPV vaccine is safe in patients with stable JIA and regardless of the use of medications the vaccine assures an adequate degree of protection for a certain time.
KW - autoimmune disease
KW - bivalent papillomavirus vaccine
KW - HPV
KW - juvenile idiopathic arthritis
KW - papillomavirus vaccine
KW - rheumatological disease
UR - http://www.scopus.com/inward/record.url?scp=84911475847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84911475847&partnerID=8YFLogxK
U2 - 10.1586/14760584.2014.943195
DO - 10.1586/14760584.2014.943195
M3 - Article
VL - 13
SP - 1387
EP - 1393
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
SN - 1476-0584
IS - 11
ER -